Rifabutin
General Information
Rifamycin
Restricted formulary antimicrobial: For details see OUH netFormulary
For all information regarding contra-indications, interactions, contraception, pregnancy and breastfeeding and additional information, see BNF and Summary of Product Characteristics (SPC).
Dosage
|
Indication |
Oral treatment dose |
|
Non-tuberculous mycobacterial disease (in combination with other drugs) |
450mg-600mg OD |
|
Helicobacter pylori (in combination with other drugs) |
150mg BD |
|
Tuberculosis |
See Tuberculosis section |
Renal and hepatic impairment
Renal impairment
|
eGFR (mL/min/1.73m2) |
Oral dose |
|
30 and above |
Dose as in normal renal function |
|
Less than 30 |
Use half of the normal dose. Maximum 300mg daily. |
|
HDF/High Flux |
Not dialysed. Dose as in eGFR less than 30ml/min |
|
PD |
Unlikely to be dialysed Dose as in eGFR less than 30ml/min |
Hepatic impairment
- No dose adjustment required
- Severe hepatic impairment: use with caution
References
- Pfizer Limited. Mycobutin 150 mg capsules summary of product characteristics. Electronic Medicines Compendium. Last revision of the text 05/2026. Accessed via www.medicines.org.uk Accessed 10/8/26.
- British National Formulary. Rifabutin. BNF online accessed via www.medicinescomplete.com Accessed 10/8/26.
- The Renal Drug Database. Rifabutin. Last updated 23/9/24. Accessed via https://renaldrugdatabase.com Accessed 10/8/26.
- Sanford Guide [online] Rifabutin. Last updated 6/8/26. Accessed via https://webedition.sanfordguide.com Accessed 10/8/26.